Attralus

18 articles with Attralus

• Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders

  11/17/2022

  Attralus, Inc. and Ossianix announced today that they have entered into a definitive agreement using Ossianix' brain shuttle technology to enhance the targeted delivery of novel pan-amyloid removal candidates for use in neurodegenerative disorders such as Alzheimer’s Disease.

• Attralus Announces First Subject Enrolled in Phase 1 Clinical Trial of AT-02, Its Lead Pan-Amyloid Removal Therapeutic Candidate

  10/17/2022

  Attralus, Inc. today announced that the first subject has been dosed in the Phase 1 clinical trial of AT-02, the company's lead pan-amyloid removal (PAR) therapeutic.

• Attralus Announces Presentation of Clinical Data for AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent, at the 18th International Symposium on Amyloidosis

  9/8/2022

  Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced multiple data presentations from the University of Tennessee Graduate School of Medicine for AT-01 (iodine (I-124) evuzamitide), the company’s pan-amyloid binding peptide in development as an amyloid-specific imaging agent for the diagnosis and management of all types of systemic amyloidosis.

• Attralus Announces New Preclinical Data Demonstrating Novel Human Chimeric Antigen Receptor-Macrophages (CAR-M) for Potential Amyloid Removal at 18th International Symposium on Amyloidosis

  9/6/2022

  Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced exciting new preclinical data from the University of Tennessee Graduate School of Medicine from its study on novel human chimeric antigen receptor-macrophages (CAR-M) as a potential therapeutic for amyloid clearance.

• Attralus to Present New Data on Its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis

  8/22/2022

  Attralus, Inc. today announced that new data across the Company's amyloidosis portfolio will be presented in both oral and poster presentations at the XVIII International Symposium on Amyloidosis (ISA) by Attralus, the University of Tennessee Graduate School of Medicine and the Brigham and Women's Hospital.

• 

  FDA Review: Bayer, Daiichi Sankyo, AstraZeneca and More

  8/12/2022

  Daiichi Sankyo and AstraZeneca report another first-in-class approval for Enhertu, Bayer snags an sNDA in metastatic hormone-sensitive prostate cancer and Merck faces contamination challenges with Januvia.

• Attralus Receives U.S. FDA Orphan Drug Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of Transthyretin Amyloidosis

  8/8/2022

  Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for 124 I-AT-01 (iodine (I-124) evuzamitide) as a diagnostic for the management of transthyretin amyloidosis (ATTR).

• Positive New Data from Phase 1/2 Trial of AT-01 (Iodine I-124 Evuzamitide) Presented at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

  6/14/2022

  Attralus, Inc today announced encouraging new clinical data from the University of Tennessee Graduate School of Medicine from its Phase 1/2 trial of AT-01 (Iodine I-124 evuzamitide), the company’s pan-amyloid binding peptide in development as a radiotracer for the diagnosis of multiple types of systemic amyloidosis.

• Attralus to Present New AT-01 Data at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

  6/3/2022

  Attralus, Inc., today announced that final data from the University of Tennessee Graduate School of Medicine from its Phase 1/2 trial of iodine evuzamitide (124I-AT-01), will be presented in both oral and poster presentations at the 2022 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting.

• Positive New Data from Phase 1/2 Trial of AT-01 Presented at 2022 American College of Cardiology Annual Scientific Session

  4/4/2022

  Attralus, Inc. announced encouraging new clinical data from the University of Tennessee Graduate School of Medicine from its Phase 1/2 trial of iodine evuzamitide, the company’s pan-amyloid binding peptide in development as a radiotracer for the diagnosis of systemic amyloidosis.

• Attralus Appoints James Testa as Vice President of Finance

  2/10/2022

  Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced the appointment of James Testa as Vice President of Finance.

• 

  Clinical Catch-Up: December 11-17

  12/20/2021

  It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.

• Attralus Presents Positive New Data at 2021 American Society of Hematology Annual Meeting

  12/13/2021

  Attralus, Inc. today announced encouraging new preclinical data for AT-03, the company’s first-in-class pan-amyloid removal (PAR) therapeutic being developed for the treatment of systemic amyloidosis.

• Attralus to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/22/2021

  Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, is pleased to announce the company’s participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference.

• Attralus to Present New Data at 2021 American Society of Hematology Annual Meeting

  11/4/2021

  Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced that new preclinical data for AT-03, the company’s first-in-class pan-amyloid removal therapeutic being developed for the treatment of systemic amyloidosis, will be presented at the 2021 American Society of Hematology Annual Meeting.

• Attralus Closes $116 Million Series B Financing

  9/8/2021

  Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced that it has closed a $116 million Series B financing.

• 

  BioSpace Movers & Shakers, July 30, 2021

  7/30/2021

  Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers.

• Attralus Appoints Jake Bauer to Board of DirectorsStrengthens Board with seasoned biopharmaceutical industry executive

  7/28/2021

  Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced that Jake Bauer joined the company’s Board of Directors as an independent director.